BEIJING - State-backed vaccine maker China National Biotec Group (CNBG) is hopeful of two of its novel coronavirus vaccine candidates receiving conditional regulatory approval for general public use within the year, its vice-president said on Tuesday.
CNBG is discussing with relevant state authorities about the requirements for conditional approvals of the two coronavirus vaccines. If all goes well, the two vaccines could hopefully be approved conditionally within the year for use in the general public.
Zhang Yuntao, Vice-president of China National Biotec Group
China has inoculated hundreds of thousands of people under an emergency program authorized in July for essential workers and other limited groups of people considered at high risk of infection, to stave off a resurgence of the coronavirus, even as clinical trials of vaccines are still underway to prove their efficacy and safety.
Inoculating the general public with a workable vaccine is likely to be an important tool in curbing a virus that has led to over 960,000 deaths worldwide. However, expanding vaccine use prior to obtaining long-term data risks raising expert concern.
ALSO READ: China vaccine maker says shots safe amid AstraZeneca setback
“CNBG is discussing with relevant state authorities about the requirements for conditional approvals of the two coronavirus vaccines,” Zhang Yuntao told Reuters.
“If all goes well, the two vaccines could hopefully be approved conditionally within the year for use in the general public,” Zhang said in a statement to Reuters.
In China, authorities can grant conditional approval for vaccines undergoing clinical trials if deemed urgent for major public health emergencies, with assessed benefits outweighing risks.
CNBG’s two candidates are included in China’s emergency use program. One of them obtained emergency approval this month in the United Emirates where the firm is conducting a Phase 3 trial.
READ MORE: 2 virus vaccines to be available by year's end, says developer
Zhang did not specify the regulators CNBG is in talks with. China’s National Medical Products Administration did not respond to a request for comment.
CNBG is a subsidiary of state-owned China National Pharmaceutical Group Co Ltd (Sinopharm).
Medical-social service network can enhance holistic well-being
HK's education system must be reformed to ensure cultural security
SAR's unique role ensures international financial-center status
Chinese path to modernization hailed
HK home prices post four-month high
Copyright 1995 - 2023. All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily. Without written authorization from China Daily, such content shall not be republished or used in any form.
HONG KONG NEWS